三种基于血浆的 microRNAs 作为子宫内膜癌的有效诊断生物标志物。

Three plasma-based microRNAs as potent diagnostic biomarkers for endometrial cancer.

机构信息

Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

出版信息

Cancer Biomark. 2021;31(2):127-138. doi: 10.3233/CBM-200972.

DOI:10.3233/CBM-200972

PMID:33896823

Abstract

BACKGROUND

MicroRNAs (miRNAs), with noticeable stability and unique expression pattern in plasma of patients with various diseases, are powerful non-invasive biomarkers for cancer detection including endometrial cancer (EC).

OBJECTIVE

The objective of this study was to identify promising miRNA biomarkers in plasma to assist the clinical screening of EC.

METHODS

A total of 93 EC and 79 normal control (NC) plasma samples were analyzed using Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) in this four-stage experiment. The receiver operating characteristic curve (ROC) analysis was conducted to evaluate the diagnostic value. Additionally, the expression features of the identified miRNAs were further explored in tissues and plasma exosomes samples.

RESULTS

The expression of miR-142-3p, miR-146a-5p, and miR-151a-5p was significantly overexpressed in the plasma of EC patients compared with NCs. Areas under the ROC curve of the 3-miRNA signature were 0.729, 0.751, and 0.789 for the training, testing, and external validation phases, respectively. The diagnostic performance of the identified signature proved to be stable in the three public datasets and superior to the other miRNA biomarkers in EC diagnosis. Moreover, the expression of miR-151a-5p was significantly elevated in EC plasma exosomes.

CONCLUSIONS

A signature consisting of 3 plasma miRNAs was identified and showed potential for the non-invasive diagnosis of EC.

摘要

背景

微小 RNA（miRNA）在患有各种疾病的患者的血浆中具有显著的稳定性和独特的表达模式，是癌症检测的强大非侵入性生物标志物，包括子宫内膜癌（EC）。

目的

本研究的目的是确定有前途的 miRNA 生物标志物在血浆中以协助 EC 的临床筛查。

方法

在这个四阶段实验中，使用定量实时聚合酶链反应（qRT-PCR）分析了 93 个 EC 和 79 个正常对照（NC）血浆样本。通过接收者操作特征曲线（ROC）分析评估诊断价值。此外，还进一步探索了鉴定出的 miRNA 在组织和血浆外泌体样本中的表达特征。

结果

与 NC 相比，EC 患者血浆中 miR-142-3p、miR-146a-5p 和 miR-151a-5p 的表达明显过表达。3- miRNA 特征的 ROC 曲线下面积在训练、测试和外部验证阶段分别为 0.729、0.751 和 0.789。鉴定出的特征在三个公共数据集的诊断性能证明是稳定的，并且在 EC 诊断中优于其他 miRNA 生物标志物。此外，miR-151a-5p 在 EC 血浆外泌体中的表达明显升高。